Article ID Journal Published Year Pages File Type
3269825 HPB 2011 5 Pages PDF
Abstract
Genexol proved to be an effective treatment for gemcitabine-resistant PDA. These data combined with the successful clinical use of genexol in Phase II trials of other malignancies suggests it maybe an effective treatment for pancreatic cancer, specifically for those patients resistant to gemcitabine.
Keywords
Related Topics
Health Sciences Medicine and Dentistry Endocrinology, Diabetes and Metabolism
Preview
Genexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinoma
Authors
, , , ,